OnabotulinumtoxinA, widely known as Botox, holds official Food and Drug Administration approval for the treatment of severe primary axillary hyperhidrosis, which refers to excessive underarm sweating that cannot be managed adequately by topical agents. Dermatologists and specialized physicians also utilize Botox off-label to treat hyperhidrosis affecting other localized regions, such as the palms of the hands, soles of the feet, and the craniofacial area, by temporarily blocking the chemical signals from nerves that stimulate sweat glands.